Canadian International Pharma Corp. Closes Second Tranche of Non-Brokered Private Placement

West Vancouver, British Columbia, August 5, 2016 – Canadian International Pharma Corp. (the “Company” or “CIPC”) – Further to the Company’s news releases of May 17, 2016, July 6, 2016, July 8, 2016 and August 3, 2016, CIPC is pleased to announce that the Company has closed the second tranche of its non-brokered private placement (the “Private Placement”). Under the first tranche, the Company raised $370,000 by the issuance of 3,700,000 units (the “Units”) at $0.10 per Unit, and under the second tranche, the Company has raised an additional $20,000 by the issuance of 200,000 Units. Each Unit consists of one common share and one share purchase warrant, with each warrant entitling the holder to purchase an additional common share for a period of one year at an exercise price of $0.15.  All of the securities issued pursuant to the second tranche of the Private Placement are subject to a hold period expiring on December 6, 2016. If additional subscriptions are received during the month of August 2016, the Company will proceed with a third (final) tranche of this Private Placement (which would close on or before the first week of September 2016).

The Company intends to use the proceeds from this Private Placement for financing the continued development and pursuit of business opportunities in the area of pharmaceutical and neutraceutical manufacturing and distribution and for general working capital purposes.

About Canadian International Pharma Corp.

Canadian International Pharma Corp. (“CIPC” or the “Company”) is an emerging multi-faceted pharmaceutical company that is in the process of developing generic and nutraceutical drug manufacturing, distribution and sales. CIPC has recently launched its PharmaCert Program.  PharmaCert is a certification program for testing and measuring finished dosage forms of nutraceutical and pharmaceutical medications. The Company has also aligned itself with Canadian and US manufacturers with the objective of manufacturing generics and nutraceuticals for Canadian and overseas markets.

For further information, contact Mr. Clive Shallow, Shareholder Communications, at 604-922-2030, or visit the Company’s website at

“Douglas L. Mason”
Douglas L. Mason, Chief Executive Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this release.


This release includes certain statements that may be deemed “forward-looking statements” within the meaning of applicable securities legislation. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “suspects”, “intends”, “estimates”, “projects”, ”targets”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those expressed in, or implied by, this forward looking information.  Factors that could cause actual results to differ materially from those in forward-looking statements include such matters as market prices for the Company’s anticipated products, regulatory approvals required for the Company’s business plans, continued availability of capital and financing, and general economic, market or business conditions.  Any forward-looking statements are expressly qualified in their entirety by this cautionary statement.  Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date such statements were made. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.